Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Gains from Sales and Divestitures: 2022-2024

Historic Gains from Sales and Divestitures for Kiniksa Pharmaceuticals International (KNSA) over the last 3 years, with Dec 2024 value amounting to $680,031.

  • Kiniksa Pharmaceuticals International's Gains from Sales and Divestitures rose 15.63% to $698,136 in Q3 2025 from the same period last year, while for Sep 2025 it was $698,136, marking a year-over-year increase of 15.63%. This contributed to the annual value of $680,031 for FY2024, which is 30.41% up from last year.
  • As of FY2024, Kiniksa Pharmaceuticals International's Gains from Sales and Divestitures stood at $680,031, which was up 30.41% from $521,440 recorded in FY2023.
  • Kiniksa Pharmaceuticals International's Gains from Sales and Divestitures' 5-year high stood at $680,031 during FY2024, with a 5-year trough of $250,805 in FY2022.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $521,440 (2023), whereas its average is $484,092.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Gains from Sales and Divestitures surged by 107.91% in 2023, and later tumbled by 30.41% in 2024.
  • Kiniksa Pharmaceuticals International's Gains from Sales and Divestitures (MRY) stood at $250,805 in 2022, then skyrocketed by 107.91% to $521,440 in 2023, then soared by 30.41% to $680,031 in 2024.
  • Its last three reported values are $680,031 in FY2024, $521,440 for FY2023, and $250,805 during FY2022.